Molecular Medicine

​​​​​Dr Betty Diamond (Editor-in-Chief) graduated with a BA from Harvard University and an MD from Harvard Medical School. She performed a residency in Internal Medicine at Columbia Presbyterian Medical Center and received postdoctoral training in immunology at the Albert Einstein College of Medicine.
Dr Diamond has headed the Rheumatology Divisions at Albert Einstein School of Medicine and at Columbia University Medical Center. She also directed the Medical Scientist Training Program at Albert Einstein School of Medicine for many years. She is currently head of the Center for Autoimmune, Musculoskeletal and Hematopoietic Diseases at The Feinstein Institutes for Medical Research and Director of the PhD and MD/PhD programs at the Zucker School of Medicine at Hofstra-Northwell.
A past president of the American Association of Immunology, Dr Diamond has also served on the Board of Directors of the American College of Rheumatology and the Scientific Council of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Dr Diamond is a Fellow of the American Association for the Advancement of Science (AAAS), a member of the National Academy of Medicine, and a member of the National Academy of Sciences.

Dr Valentin Pavlov, PhD (Executive Editor) is a Professor at the Feinstein Institutes for Medical Research, Northwell Health, and Professor at the Zucker School of Medicine at Hofstra/Northwell. He received his PhD in Physiology, Pathophysiology and Pharmacology from Sofia University "St. Kliment Ohridski" in Sofia, Bulgaria. Following a post-doc at Robert Gordon University, Aberdeen, UK, he joined the Feinstein Institutes in 2002. 
Dr Pavlov’s current research focuses on the role of the brain and vagus nerve cholinergic signaling in the regulation of inflammation and metabolism, and the use of novel cholinergic therapeutic approaches in sepsis and obesity-driven disorders. 
Dr Pavlov is a member of several scientific societies, including Society for Neuroscience, American Physiological Society, American Association of Immunologists, and American Society for Pharmacology and Experimental Therapeutics. He is an Elected Fellow of the American Institute for Medical and Biological Engineering and President of the International Society for Autonomic Neuroscience.

Dr. Rosamaria (Maria) Ruggieri, PhD (Managing Editor) is an Associate Professor at the Karches Center for Oncology Research, Feinstein Institutes for Medical Research and at the Department of Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. Dr. Ruggieri received her PhD in Biology from the Weizmann Institute of Science, Rehovot, Israel. After post-doc at DNAX, Palo Alto, and 6 years at ONYX Pharmaceuticals, Richmond, California, she moved to New York where she has been working at the Feinstein Institutes since 2001. Her work has centered on signaling molecules involved in cancer and during the last ten years it has focused on identifying new therapies for pediatric brain tumors.

Dr. Shabirul Haque, PhD, (Managing Editor) is an Investigator at The Feinstein Institute for Medical Research, Northwell Health, Manhasset, New York. Dr. Haque received his MS (Biotechnology) from Aligarh Muslim University (AMU) and PhD (Biomedical sciences) from All India Institute of Medical Sciences (AIIMS), New Delhi, India. He joined the Feinstein Institute for Medical Research in 2009.
Over the span of 20 years of his research career he acquired vast experience in numerous areas, including in vaccine research (conjugate, recombinant and peptide vaccine) leading to patent and technology transfer. His work in cancer research studying B cell biology, the pathogenesis of acute lymphoid leukemia, the role extracellular vesicles (EVs) and innate immunity in cancer development, lead to multiple peer-reviewed publications. Most recently, he is focusing on understating autoimmune diseases.

Dr. Sonya VanPatten, PhD (Coordinating Editor) is a research scientist in the Institute of Molecular Medicine at the Feinstein Institutes for Medical Research. Dr. VanPatten received her PhD from the Albert Einstein College of Medicine (Bronx, NY, USA) in the Department of Biochemistry. She later did a post-doc at the Feinstein Institutes in the Department of Medicinal Chemistry.
Dr. VanPatten’s research has been in the fields of lipid metabolism, obesity, immunology and autoimmune disease, neuroscience, and drug discovery and development. Currently, she focuses on scientific writing, synopsis, consultation, project management, and editorial aspects of the Institutes’ journals.

The Feinstein Institutes Editorial Team and BMC Rejuvenate Molecular Medicine - 30 July 2018

In her 2017 TEDMED Talk, Editor-in-Chief Dr Betty Diamond discusses the latest insights in autoimmune disease research, and the pivotal role that patients play in studies.

The Editors of Molecular Medicine welcome authors to send any pre-submission inquiries they might have, here. We ask that you please include “Pre-submission inquiry” in the subject line of your email and that you include the title and abstract of your proposed submission within the message. Our Editors will do their best to respond to you in a timely manner.

If you enjoy Molecular Medicine, we invite you to visit Feinstein’s Bioelectronic Medicine (published by BMC). Bioelectronic Medicine focuses on the regulatory functions of the nervous system and technologies that record, stimulate, or block neural signaling to affect specific molecular mechanisms in health and disease. It also features bioelectronic approaches for monitoring and controlling biological processes and for providing insights into disease pathogenesis that can be utilized in new treatments of inflammatory, neurodegenerative, gastrointestinal, and cardiovascular diseases, paralysis, and many other conditions.

Molecular Medicine is published in partnership with The Feinstein Institutes for Medical Research. As the research arm of Northwell Health, the largest healthcare provider in New York, it is home to 50 research laboratories and to clinical research throughout dozens of hospitals and outpatient facilities. The Feinstein Institutes include 4,000 researchers and staff who are making breakthroughs in molecular medicine, genetics, oncology, brain research, mental health, autoimmunity, and bioelectronic medicine – a new field of science that has the potential to revolutionize medicine. For more information about how the Feinstein Institutes empower imagination and pioneers discovery, visit FeinsteinInstitute.org.